ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1549

Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy

Magdalena Cavalieri1, Roger Rolon Campuzano1, Emilce E Schneeberger2, Fernando Dal Pra3, Dafne Capelusnik4, Carolina Ayelen Isnardi5, Marina Natalia Fornaro6 and Gustavo Citera7, 1Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Reumatology, Instituto de Rehabilitación Psicofísica, Argentina, CABA, Argentina, 5Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, 6Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina, 7Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: adverse events and combination therapies, Biologic agents

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

According to clinical practice guidelines for patients with rheumatoid arthritis (RA), after failure to a c-DMARD (conventional disease modifying antirheumatic drug) can be chosen either by the combination with another c-DMARD, or by the addition of b-DMARD (biological) or ts-DMARD (target synthetic). The most frequent c-DMARD combination therapy in our country is methotrexate (MTX) plus lefunomide (LEF).

The objective is to compare the survival and safety of treatment between two cohorts of patients with RA who have failed to c-DMARD monotherapy: one with combination of MTX + LEF (cohort A) and the other with the first b-DMARD (cohort B).

Methods:

Patients ≥18 years old with RA (ACR 1987 or ACR/EULAR 2010 criteria), who received treatment with MTX plus LEF or with the first b-DMARD therapy after failing c-DMARD monotherapy were included. Sociodemographic, clinical and therapeutic variables were recorded. Disease activity was assessed by DAS28. The adverse events (AE) that occurred during the treatment, the severity of them, as well as, the interruptions of the treatment were consigned. The causes of discontinuation and survival of both types of treatment were evaluated. Statistical analysis: Descriptive statistics. Chi 2 test, Student’s T test and/or Mann Whitney test. Multiple logistic regression analysis. Kaplan Meier curves and Log Rank test for survival analysis.

Results:

202 patients were included, median age was 58 years old (IQR 50.7-65), 86.6% were female and the median disease duration was 15 years (IQR 9-22). 69.8% had associated comorbidities. 100 patients (49.5%) were in cohort A and 102 (50.5%) were in cohort B. No baseline differences were found related to the clinical characteristics, except for the prevalence of previous tuberculosis (Cohort A 5.2% vs cohort B 0%, p= 0.02) and heart failure (Cohort A 7.4% vs cohort B 1%, p= 0.03). We did not observe differences in treatment survival between both cohorts [Cohort A: mean 121.2 months (95%CI: 100.3-142) and cohort B: mean 77.1 months (95%CI 63.3-91), p = 0.2]. 47.6% of cohort A permanently or temporarily suspended therapy vs 52.4% of cohort B (p = 0.67), being the most frequent causes of discontinuation: for cohort A inefficacy (31.1%) and AE for cohort B (55.8%). 56.9% suffered at least one AE and 60% of them were receiving concomitant corticosteroids. The infections were more frequent in cohort B 39.7% vs cohort A 19.6% (p = 0.02). In multivariate analysis, adjusting for age and disease duration, corticosteroid treatment was associated with the presence of AE (OR: 19.8, 95% CI: 6.23-57.6, p <0.001) regardless of the type of treatment, and the use of biological therapy was associated with higher risk of infections (OR 2.7, 95%CI: 1.15-6.34, p = 0.02) regardless of the use of concomitant corticosteroids.

Conclusion:

Treatment survival in both cohorts was comparable. The frequency of infections was higher in cohort with b-DMARD. Concomitant treatment with steroids increased the risk of AE, regardless of the type of treatment.


Disclosure: M. Cavalieri, None; R. Rolon Campuzano, None; E. E. Schneeberger, None; F. Dal Pra, None; D. Capelusnik, None; C. A. Isnardi, None; M. N. Fornaro, None; G. Citera, Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, Genzyme, Novartis, Pfizer Inc, Roche, 5.

To cite this abstract in AMA style:

Cavalieri M, Rolon Campuzano R, Schneeberger EE, Dal Pra F, Capelusnik D, Isnardi CA, Fornaro MN, Citera G. Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparison-of-adverse-events-and-survival-of-treatment-in-patients-with-rheumatoid-arthritis-receiving-combined-treatment-of-methotrexate-and-leflunomide-versus-those-receiving-biological-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-adverse-events-and-survival-of-treatment-in-patients-with-rheumatoid-arthritis-receiving-combined-treatment-of-methotrexate-and-leflunomide-versus-those-receiving-biological-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology